An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Clinical trial NCT02211222 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT02211222
- Sponsor
- Eisai Inc.
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
- Primary completion
- 2015-08-01
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.